Your session is about to expire
← Back to Search
TTFields + SRS + Temozolomide for Glioblastoma
Study Summary
This trial is testing a new combination therapy for newly diagnosed glioblastoma (GBM). The safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) will be determined.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My platelet count is healthy without needing blood transfusions in the past week.I am not on medication for tuberculosis or HIV.I am a woman who can have children and have a negative pregnancy test, or I am postmenopausal or surgically sterile.I have other health conditions or illnesses.I have cirrhosis but my liver still works relatively well.I am not currently on any cancer treatments like chemotherapy or targeted therapy.I am 18 years old or older.I have been newly diagnosed with glioblastoma or its molecular equivalent.My organs are working well, as confirmed by recent tests.My white blood cell count is healthy without needing medication for the past week.My hemoglobin level is at least 9 g/dL, or has been corrected to this level.I can care for myself but may need occasional help.I have had chemotherapy or radiotherapy for brain cancer.I have not had a severe illness in the last 28 days.I have had cancer before, but it was either skin cancer, cervical or bladder cancer in situ, or any cancer treated over 3 years ago.I am currently taking specific medications while undergoing TTFields and SRS treatment.My tumor is smaller than 5 cm, or if larger, it fits within a specific volume limit.
- Group 1: Novo-TTF
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What prior research has been done on the effectiveness of Stereotactic radiosurgery (SRS)?
"At present, 215 medical trials are underway exploring Stereotactic radiosurgery (SRS), with 23 of those in the third phase. While Seoul, Songpa is home to most investigations into this technique, there are 4777 other sites running studies regarding SRS across the globe."
Are any new participants eligible to join this research endeavor?
"Affirmative. Patients are currently being recruited for this clinical trial, details of which were initially posted on the 21st of May 2021 and recently updated on August 17th 2022."
To what maladies has Stereotactic radiosurgery (SRS) been clinically demonstrated to be efficacious?
"When dealing with nitrosourea treatment, advance directives and refractory advanced mycosis fungoides, Stereotactic Radiosurgery (SRS) can be employed as an efficacious therapeutic approach."
Has the government approved of Stereotactic Radiosurgery (SRS) for public use?
"SRS is still in its early stages of research, so it has been assigned a score of 1. This reflects the limited evidence available on this treatment's safety and efficacy."
What is the scale of enrollment for this research initiative?
"Affirmative. The clinical trial is still recruiting, as indicated on its page hosted on clinicaltrials.gov. It was initially posted on May 21st 2021 and the last update was August 17th 2022; 12 volunteers are being sought out from a single medical centre."
Is this research endeavor pioneering in its approach?
"Globally, there are 36 countries with 940 cities encompassing 215 active clinical trials regarding Stereotactic Radiosurgery (SRS). The first trial of its kind was conducted in 2002 by Schering-Plough. This study featured 60 patients and achieved Phase 2 drug approval. Since then, 315 more studies have been completed."
Share this study with friends
Copy Link
Messenger